GO
Loading...

Amgen Inc

More

  • Midday Glance: Biotechnology companies Thursday, 21 Aug 2014 | 1:22 PM ET

    Amgen Inc. rose$. 03 or percent, to $132.71. Biogen Idec fell $2.14 or. 6 percent, to $340.45. Celgene Corp. rose$. 02 or percent, to $92.02.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Lilly psoriasis drug fares well in late-stage test Thursday, 21 Aug 2014 | 8:55 AM ET

    INDIANAPOLIS— Drugmaker Eli Lilly and Co. said its potential psoriasis treatment fared better than both a fake drug and a competitor's product during late-stage testing on patients with the most common form of the skin disease.

  • Final Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 6:02 PM ET

    Amgen Inc. fell$. 34 or. 3 percent, to $132.68. Biogen Idec fell $3.26 or. 9 percent, to $342.58. Celgene Corp. rose$. 64 or. 7 percent, to $92.00.

  • Midday Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 1:49 PM ET

    Amgen Inc. fell$. 35 or. 3 percent, to $132.67. Biogen Idec fell $2.66 or. 8 percent, to $343.18. Celgene Corp. rose $1.38 or 1.5 percent, to $92.74.

  • Early Glance: Biotechnology companies Wednesday, 20 Aug 2014 | 12:21 PM ET

    Amgen Inc. fell$. 61 or. 5 percent, to $132.41. Biogen Idec fell $1.68 or. 5 percent, to $344.16. Celgene Corp. rose $1.47 or 1.6 percent, to $92.83.

  • Final Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 6:08 PM ET

    Amgen Inc. fell$. 20 or. 2 percent, to $133.02. Biogen Idec rose $1.24 or. 4 percent, to $345.84. Celgene Corp. rose$. 05 or. 1 percent, to $91.36.

  • Midday Glance: Biotechnology companies Tuesday, 19 Aug 2014 | 4:03 PM ET

    Amgen Inc. fell $1.29 or 1.0 percent, to $131.93. Biogen Idec fell$. 31 or. 1 percent, to $344.29. Celgene Corp. rose$. 10 or. 1 percent, to $91.41.

  • LOS ANGELES, Aug 17- Biotech drug production techniques based on plants, which may prove to be faster, higher yielding and cheaper than current methods using mammalian cells, haven't caught on with the biggest pharmaceutical companies.

  • US STOCKS-Futures point to flat open after recent rally Thursday, 14 Aug 2014 | 8:54 AM ET

    *Cisco down in premarket after results, outlook. NEW YORK, Aug 14- U.S. stock index futures pointed to a flat open on Thursday as investors found few reasons to buy following a sharp rally in the previous session and amid signs of weakness in Europe and ongoing uncertainty over Ukraine.

  • Early movers: WMT, KSS, GE, UPS, AMGN, GMCR & more Thursday, 14 Aug 2014 | 7:40 AM ET
    Traders on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • Aug 13- Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.1 percent at $124.66 in after-hours trading on Wednesday.

  • After-hours buzz: Cisco, NetApp, Amgen and more Wednesday, 13 Aug 2014 | 5:04 PM ET
    Traders on the floor of the New York Stock Exchange.

    Take a look at some of Wednesday's after-hours movers: Cisco, NetApp, Amgen and more

  • Aug 13- A Phase 3 trial of Amgen Inc's Kyprolis drug failed to show it could extend survival compared to standard care for patients with advanced multiple myeloma, a type of blood cancer that develops in the bone marrow. Shares of Amgen were down 2.3 percent at $124.41 in after-hours trading on Wednesday.

  • The R&D Hall of Fame: Who makes the cut? Wednesday, 6 Aug 2014 | 6:00 AM ET

    Using the CNBC RQ 50 measure for R&D productivity, we've identified an elite group of companies that merit election to an R&D hall of fame.

  • Aug 5- Regeneron Pharmaceuticals Inc on Tuesday reported higher-than-expected quarterly revenue and earnings on surging demand for its Eylea treatment for macular degeneration, and stuck to its full-year sales forecast for the drug.

  • Cramer: Dozens of stocks that could work higher Monday, 4 Aug 2014 | 6:56 PM ET

    Cramer likes to review the S&P 500’s Daily Action Charts in an effort to find stocks that could work higher.

  • US STOCKS-Wall St gains on earnings; utilities sag Monday, 4 Aug 2014 | 2:38 PM ET

    *Berkshire Hathaway shares up after results. NEW YORK, Aug 4- U.S. stocks were slightly positive in trading on Monday afternoon, boosted by earnings including Berkshire Hathaway's results, though gains were offset by drops in high-dividend payers in the utilities sector.

  • Midday movers: Amgen, Groupon, Walt Disney & more Monday, 4 Aug 2014 | 1:02 PM ET
    A live market monitor is viewed on the floor of the New York Stock Exchange (NYSE).

    Some of Monday's midday movers:

  • *Berkshire Hathaway shares up after results. NEW YORK, Aug 4- U.S. stocks were little changed in volatile trading Monday as earnings, including those of Warren Buffett's Berkshire Hathaway, were partly offset by drops in high-yielding dividend stocks in the utilities sector.